Ixekizumab Dosage

Medically reviewed on January 11, 2018.

Usual Adult Dose for Plaque Psoriasis

160 mg (two 80 mg injections) subcutaneously at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks

Comment:
-Evaluate patients for tuberculosis (TB) infection prior to initiating therapy.

Use: For the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

Usual Adult Dose for Psoriatic Arthritis

160 mg (two 80 mg injections) subcutaneously at Week 0, followed by 80 mg at every 4 weeks

Comments:
-Evaluate patients for tuberculosis (TB) infection prior to initiating therapy.
-For psoriatic arthritis patients with coexistent moderate-to-severe plaque psoriasis, use the dosing regimen for plaque psoriasis.
-This drug may be administered alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).

Use: For the treatment of adult patients with active psoriatic arthritis

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Storage requirements:
-Protect from light until use.
-Store refrigerated at 2C to 8C (36F to 46F).
-Do not freeze.
-Do not use this drug if it has been frozen.
-Do not shake.
-Discard the single-dose autoinjector or syringe after use in a puncture-resistant container.
-Not made with natural rubber latex.

Reconstitution/preparation techniques:
Preparation for Use of Autoinjector and Prefilled Syringe:
-Before injection, remove autoinjector or prefilled syringe from the refrigerator and allow it to reach room temperature (30 minutes) without removing the needle cap.
-Inspect visually for particulate matter and discoloration prior to administration. The solution should be clear and colorless to slightly yellow.
-Do not use if the liquid contains visible particles, is discolored or cloudy (other than clear and colorless to slightly yellow).
-The product does not contain preservatives, therefore discard any unused product remaining in the autoinjector or prefilled syringe.
-Instruct patients using the autoinjector or prefilled syringe to inject the full amount (1 mL), which provides 80 mg of drug, according to the directions provided in the manufacturer product information.

General:
-There are 2 delivery systems (i.e., autoinjector and prefilled syringe). The instructions for use of each system contain more detailed instructions on the preparation and administration.
-This drug is intended for use under the guidance and supervision of a physician.
-Patients may self-inject after training in subcutaneous injection technique using the autoinjector or prefilled syringe.
-Administer each injection at a different anatomic location (such as upper arms, thighs or any quadrant of the abdomen) than the previous injection, and not into areas where the skin is tender, bruised, erythematous, indurated, or affected by psoriasis.
-Administration in the upper, outer arm may be performed by a caregiver or healthcare provider.
-If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled intervals.

Patient advice:
-Inform patients that this drug may lower the ability of their immune system to fight infections.
-Instruct patients of the importance of communicating any history of infections to the healthcare provider, and contacting their healthcare provider if they develop any symptoms of infection.
-Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer